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Abstract
Ouabain is an endogenous substance occurring in the plasma in the
nanomolar range, that has been proposed to increase vascular resist-
ance and induce hypertension. This substance acts on the α-subunit of
Na+,K+-ATPase inhibiting the Na+-pump activity. In the vascular
smooth muscle this effect leads to intracellular Na+ accumulation that
reduces the activity of the Na+/Ca2+ exchanger and to an increased
vascular tone. It was also suggested that circulating ouabain, even in
the nanomolar range, sensitizes the vascular smooth muscle to vaso-
pressor substances. We tested the latter hypothesis by studying the
effects of ouabain in the micromolar and nanomolar range on phenyl-
ephrine (PE)-evoked pressor responses. The experiments were per-
formed in normotensive and hypertensive rats in vivo, under anesthe-
sia, and in perfused rat tail vascular beds. The results showed that
ouabain pretreatment increased the vasopressor responses to PE in
vitro and in vivo. This sensitization after ouabain treatment was also
observed in hypertensive animals which presented an enhanced vaso-
pressor response to PE in comparison to normotensive animals. It is
suggested that ouabain at nanomolar concentrations can sensitize
vascular smooth muscle to vasopressor stimuli possibly contributing
to increased tone in hypertension.
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Introduction
Recently, ouabain has been described as
an endogenous substance occurring in the
nM range in the plasma of hypertensive sub-
jects (1-3). These findings have strength-
ened the proposal that ouabain can increase
vascular resistance and induce hypertension
(4). Since ouabain inhibits the Na+-pump
activity in vascular smooth muscle (VSM)
cells, two consequences of this inhibition
occur resulting from the intracellular Na+
increment (5-7). First, the membrane is de-
polarized (8,9) and second, the Na+/Ca2+
exchanger activity is reduced (6,7,10). Inde-
pendent of either effect, the final result is the
increase in intracellular Ca2+ concentration
and an increase in vascular tone. This possi-
bility suggests a putative role of ouabain as a
pressor agent. Indeed, a direct ouabain vaso-
constrictor effect has been reported (4) but
only at high concentrations of this com-
pound. However, a direct hypertensive ef-
fect produced by endogenous ouabain is un-
likely since very low ouabain concentrations
occur in plasma (1). Thus, another mech-
anism must be proposed to explain the pres-
sor action.
The possible explanation for this effect is
that ouabain acts on the α-subunits of Na+,K+-
ATPase inhibiting Na+-pump activity (11,12).
Na+,K+-ATPase is an integral protein of the
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plasma membrane, a heterodimer composed
of two subunits, a larger catalytic α-subunit
and a heavily glycosylated ß-subunit (11,12).
This enzyme is a receptor for digitalis com-
pounds that specifically inhibit its activity
and occurs as multiple isoforms for α- and ß-
subunits with both high and low sensitivities
to digitalis inhibition (13), according to their
catalytic α1-, α2- or α3-subunits. Recent re-
ports have indicated that the VSM displays
all 3 types of α-subunits of Na+,K+-ATPase
(14,15), including the high-affinity subunits
α2 and α3 for ouabain. Consequently, differ-
ential effects will depend on the plasma
concentration of circulating digitalis and also
on the percentage of each enzyme isoform
present in tissue.
Since the Na+-pump extrudes Na+ from
the cells its failure leads to the accumulation
of intracellular Na+ which is followed by an
intracellular Ca2+ increment (6). Even if the
initially induced myoplasmic Ca2+ increment
is small, the amplifier action of the sarco-
plasmic reticulum (SR) favors the possibil-
ity of an increased vascular tone upon acti-
vation (3,16). Recently, it has been shown
that even small increments of myoplasmic
Ca2+ may increase vascular tone because of
the amplifier action of the SR (3,16). An
indication of this possibility was reported
with low ouabain concentrations (10 nM),
increasing the constrictor action of caffeine
(17) on rat aortic rings and increasing the
vasopressor responses to phenylephrine (PE)
in the isolated rat tail vascular bed from
normotensive and hypertensive rats (18-20).
In a previous report we also showed that
pretreatment with subtherapeutic doses of
ouabain enhances PE vasopressor effects in
anesthetized normotensive and hypertensive
rats (21,22). If this mechanism is operative
small concentrations of ouabain would in-
crease the vascular resistance by smooth
muscle sensitization to vasopressor sub-
stances. This possibility suggests that circu-
lating ouabain may increase vascular resist-
ance by smooth muscle sensitization to va-
sopressor substances even at very low con-
centrations.
Material and Methods
In vitro experiments
Rat tail vascular beds obtained from nor-
motensive male Wistar Kyoto (WKY) and
spontaneously hypertensive (SHR) rats,
weighing 300-400 g, were used in this study.
Five to nine rats were used for each experi-
mental group.
The day before the experiments the sys-
tolic blood pressure (SBP) of the rats was
measured using the tail-cuff method (IITC
Model 29 Pulse Amplifier, IITC Inc., CA).
For the perfusion experiments the rats
were anesthetized with sodium pentobar-
bital (35 mg/kg, ip) and received 100 units of
heparin. The tail artery was then dissected
and cannulated near the insertion of the tail
using stretched PE 50 tubing. The prepara-
tions were perfused (Ismatec Reglo pump)
with Krebs-Henseleit (KH) bicarbonate
buffer solution, pH 7.4, bubbled with 5%
CO2-95% O2, containing 27.2 mM NaHCO3,
119 mM NaCl, 1 mM NaH2PO4, 1.2 mM
Figure 1 - Typical tracings dem-
onstrating the effects of 100 µM
and 10 nM ouabain treatment
on the phenylephrine (PE)-in-
duced vasopressor changes in
rat tail vascular beds from nor-
motensive Wistar Kyoto (WKY)
and hypertensive (SHR) rats.
Observe the sensitization to the
PE pressor response that occurs
after ouabain treatment.
Before AfterWKY rats
10 nM
100 mmHg
100 µM
100 mmHg
10 min
SHR rats
10 nM
Before After
100 mmHg
100 µM
10 min
PE (µg)
0.5 1.0 2.0 5.0 0.5 1.0 2.0 5.0
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MgSO4, 2.5 mM CaCl2.2H2O, 11 mM glu-
cose, 5 mM KCl and 0.03 mM EDTA, at a
constant flow of 2.5 ml/min. After a 30- to
45-min stabilization period the experimental
protocol was initiated. Randomized bolus
doses of phenylephrine (0.5, 1, 2 and 5 µg, in
0.1 ml) were injected and the developed
pressure was measured with a COBE CDX
pressure transducer connected to a Grass
7P16 preamplifier and recorded with a Grass
7 recorder. Since a constant flow was main-
tained the changes in pressure were a direct
indication of vascular resistance. The prepa-
rations were then continuously perfused with
KH plus ouabain (100 µM or 10 nM for 30
min and 60 min, respectively) and the same
protocol was repeated.
In vivo experiments
Studies were performed in 22 male Wistar
normotensive rats (NR), weighing 200 to
380 g, and 24 SHR, weighing 190 to 350 g.
The day before the experiments systolic
blood pressure of the rats was measured
using the tail-cuff method (IITC Model 29
Pulse Amplifier, IITC Inc.). Rats were anes-
thetized with urethane (1.2 g/kg, ip) supple-
mented when necessary. The jugular vein
and the carotid artery were dissected for
drug infusion and arterial blood pressure
measurements. ECG was also measured us-
ing standard procedures.
Vasopressor reactivity was tested by in-
jecting increasing concentrations of PE (0.1,
0.25 and 0.5 µg) administered in small vol-
umes (5 µl or less), before and 1 h after
ouabain treatment. The rats were divided
into 3 groups and each group was submitted
to one ouabain treatment, 18, 1.8 and 0.18
µg/kg, respectively, for 1 h. SBP, diastolic
blood pressure (DBP) and ECG were moni-
tored continuously throughout the experi-
ments.
Data were analyzed statistically by
ANOVA and the Student t-test for small
samples. A significant ANOVA was fol-
lowed by Tukey’s post hoc test. The results
are reported as means ± SEM and were
considered to be significant at the 5% level.
Results
In vitro experiments
Figure 1 shows the sensitizing effect of
100 µM ouabain on PE-evoked vasocon-
strictor responses in the tail vascular bed
from normotensive and hypertensive rats.
Before ouabain pretreatment the developed
perfusion pressure increased with PE con-
centration. The continuous perfusion of 100
µM ouabain sensitized the vessels increas-
ing the vasoconstrictor responses (20). How-
ever, since circulating ouabain concentra-
tion in the plasma of hypertensive subjects is
approximately 10 nM (1,2) the same proto-
col was repeated after 60 min pretreatment
with 10 nM ouabain in other tail vascular
beds isolated from normotensive and hyper-
tensive rats. A similar result is shown in
Figure 1 where it is seen that the sensitiza-
tion process occurred at a lower level after
10 nM ouabain. It is interesting to note that
normalizing the results obtained before and
after 10 nM ouabain the percentage increase
in pressure was higher in SHR (Figure 2).
In vivo experiments
Normotensive rats (SBP = 126 ± 1.98
mmHg) and SHR (SBP = 177 ± 3.76 mmHg)
were used for these studies. Figure 3 shows
the vascular reactivity represented by PE-
evoked pressor responses from NR and SHR
pooled together before ouabain treatments.
SHR displayed a higher systolic and dia-
stolic blood pressure than NR and systolic
PE-evoked pressor responses were higher in
the SHR group.
18 µg/kg ouabain treatment
SBP increased in both NR and SHR
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Figure 3 - Effect of phenyleph-
rine (PE) on the systolic blood
pressure (SBP) and diastolic
blood pressure (DBP) of normo-
tensive (NR) and hypertensive
(SHR) rats. *P<0.01 for compari-
son between NR and SHR;
+P<0.01 for comparison be-
tween PE and controls (ANOVA).
Figure 2 - Effect of 10 nM oua-
bain percent changes above
baseline perfusion pressure on
phenylephrine-induced pressor
responses in isolated perfused
rat tail vascular beds from hyper-
tensive (SHR) and normotensive
Wistar Kyoto (WKY) rats. Points
represent means – SEM.
*P<0.05 for comparison be-
tween before (triangles) and af-
ter (circles) 10 nM ouabain treat-
ment (ANOVA).
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groups after ouabain treatment (18 µg/kg)
and SBP values were higher in the SHR
group. PE pressor responses occurred for
both groups but were higher in the SHR
group. DBP values were also higher in the
SHR group after ouabain treatment but simi-
lar for NR (Figure 4).
1.8 µg/kg ouabain treatment
Figure 5 shows the changes of SBP and
DBP in NR and SHR groups before and after
ouabain treatment. In the NR group PE
evoked similar pressor responses for both
SBP and DBP before and after ouabain treat-
ment. In contrast, SHR showed an increase
in SBP and DBP after ouabain treatment and
PE pressor effects were enhanced.
0.18 µg/kg ouabain treatment
With this dose nanomolar levels of circu-
lating ouabain might be attained and still
produce similar effects as those observed
with the 1.8 µg/kg ouabain dose (Figure 6).
Again, very low doses of ouabain enhanced
the PE-evoked pressor response of SHR,
showing that these animals are more sensi-
tive to ouabain.
Discussion
The existence of a plasma natriuretic fac-
tor that inhibits Na+,K+-ATPase has been
suspected for many years. A few years ago
ouabain, a steroid compound that has been
identified in plasma and tissue extracts and
in the adrenal cortex, has been suggested as
the source of this compound (1-3).
Ouabain inhibits the Na+-pump by bind-
Systolic Diastolic
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Figure 4 - Effects of increasing
doses of phenylephrine (PE) on
the systolic blood pressure
(SBP) and diastolic blood pres-
sure (DBP) of normotensive (NR)
and hypertensive (SHR) rats be-
fore and after 1-h treatment with
18 µg/kg ouabain. Column
height indicates the mean and
the bar the SEM. *P<0.05 for
comparison between before and
after ouabain treatment (ANOVA).
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ing to the α-subunits of the enzyme (11,12).
Since the heart, vessels, kidneys and nervous
tissue carry at least two isoforms of the
enzyme (12-14), profound effects on ho-
meostatic mechanisms may be produced by
ouabain. One of these mechanisms is the
regulation of blood pressure. By inhibiting
the Na+-pump of VSM ouabain increases the
intracellular Na+ concentration leading to two
main effects, membrane depolarization and
reduced Na+/Ca2+ exchanger activity (6-9).
Both effects result in an increase in intracel-
lular Ca2+ concentration and vascular tone.
Having such actions ouabain could play a
central role in the development of hyperten-
sion (23). Many reports suggested such a
role since ouabain can produce hypertension
during long-term administration in rats (4)
and potentiate serotonin-evoked contractions
of aortic rings (17). However, a direct pres-
sor effect is unlikely since plasma ouabain
concentrations occur at nanomolar levels
(1). Despite these considerations, ouabain
could also increase vascular tone by other
mechanisms. Recently, it has been shown
that small increments of myoplasmic Ca2+
may produce increased vascular tone be-
cause of the amplifier action of the SR (3,16).
The possibility of such occurrence has been
shown recently with low ouabain concentra-
tions (10 nM) that increased caffeine-evoked
contractions in rat aortic rings (17).
We tested the hypothesis that ouabain
increases vascular resistance by smooth
muscle sensitization to vasopressor sub-
stances using a perfused rat tail vascular bed
preparation from normotensive and hyper-
tensive rats. This preparation displayed an
intrinsic basal tone and a high sensitivity to
vasopressor substances. Also, since many in
vitro experiments, both biochemical or
physiopharmacological, have been per-
formed with the rat tail artery, the present
preparation permits a correlation between
Before
After
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130
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*
550
Braz J Med Biol Res 30(4) 1997
D.V. Vassallo et al.
these studies and functional experiments
(14,24,25).
We also tested this hypothesis in vivo
using anesthetized normotensive and hyper-
tensive rats. The results showed that in both
rat strains ouabain pretreatment affected the
pressor responses to PE. Without any treat-
ment SHR displayed higher values of SBP
and DBP both before and after PE-evoked
pressor responses.
All ouabain treatments increased SBP
and DBP and enhanced PE-evoked pressor
responses in SHR. However, NR only showed
this response after 18 µg/kg ouabain treat-
ment. The lower doses (1.8 and 0.18 µg/kg,
subtherapeutic doses) did not change the
arterial blood pressure and had no effects on
the PE-evoked pressor responses. These re-
sults suggest that a) SHR display higher
arterial blood pressure levels than NR even
during PE-evoked pressor responses, b) oua-
bain sensitizes SHR and NR to PE-evoked
pressor responses when therapeutic doses
are used, and c) subtherapeutic doses of
ouabain only show effects in the SHR strain.
The expression of Na+,K+-ATPase and
its α-isoform is known to be regulated by
multiple factors such as developmental stages
(26), hormones (27) and the occurrence of
hypertension (15). Also, it has been shown
that α-subunits of Na+,K+-ATPase consist of
different α1-, α2- and α3-subunits with dif-
ferent affinities for digitalis (13). Since the
Na+,K+-ATPase isoforms may change in sev-
eral situations, the maintenance of the sensi-
tizing mechanism could be of clinical rel-
evance. In the present study we investigated
if the sensitization mechanism is operative
in normotensive and hypertensive rats. The
results presented here suggest that the sensi-
tization mechanism is operative in both nor-
motensive and hypertensive animals.
A possible explanation for this behavior
may be the existence of a similar or in-
creased abundance of the α3-isoform in both
normotensive and hypertensive rat tail vas-
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Figure 5 - Effects of increasing
doses of phenylephrine (PE) on
the systolic blood pressure (SBP)
and diastolic blood pressure
(DBP) of normotensive (NR) and
hypertensive (SHR) rats before
and after 1-h treatment with 1.8
µg/kg ouabain. Column height in-
dicates the mean and the bar the
SEM. *P<0.05 for comparison
between before and after oua-
bain treatment (ANOVA).
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Figure 6 - Effects of increasing
doses of phenylephrine (PE) on
the systolic blood pressure
(SBP) and diastolic blood pres-
sure (DBP) of normotensive (NR)
and hypertensive (SHR) rats be-
fore and after 1-h treatment with
0.18 µg/kg ouabain. Column
height indicates the mean and
the bar the SEM. *P<0.05 for
comparison between before and
after ouabain treatment (ANOVA).
cular beds since ouabain binds preferentially
to this isoform. However, to our knowledge
only Songu-Mize et al. (28) and Herrera et
al. (15) presented evidence showing upregu-
lation of the Na+-pump activity and of α1-
mRNA in the rat tail artery and aorta, respec-
tively, together with a downregulation of the
α2-mRNA as a result of DOCA-salt hyper-
tension. An increase in the activity of the
Na+-pump would favor relaxation during hy-
pertension. This increased activity even re-
sulting from the α1-isoform may be inhibited
by ouabain at levels sufficient to produce or
maintain the sensitization mechanism. Our
results, however, cannot discriminate which
mechanism is responsible for this sensitiza-
tion effect.
We conclude that the sensitization pro-
cess to vasopressor substances that occurs at
nanomolar ouabain concentrations in plasma
is operative even in hypertensive animals
and may contribute to the increase and main-
tenance of vascular tone in hypertension.
Systolic Diastolic
Before
After
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